RXi Pharmaceuticals
  • About Us
    • Leadership
    • Career Opportunities
  • Products
    • Abstral®
  • Clinical Development
    • Pipeline
    • Clinical Trials
    • NeuVax™ (nelipepimut-S)
    • FBP (E39)
    • Technology
  • Business Development
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Email Alerts
    • Corporate Governance
    • Analyst Coverage
  • News
  • Resources
Discovery. Delivery. Development. Technology

  • Stock Information
  • Press Releases
  • Events & Presentations
  • SEC Filings
  • Email Alerts
  • Corporate Governance
  • Analyst Coverage

SEC Filings


  
Filing Description Date Filed Sorted Descending Size  
8-K current report May 16, 2013 29.6 KB  
10-Q quarterly report May 9, 2013 1.6 MB  
8-K current report May 9, 2013 72.8 KB  
8-K current report May 2, 2013 38.2 KB  
4 ashton, william Apr 30, 2013 24.4 KB  
3 ashton william Apr 30, 2013 20.8 KB  
DEFA14A definitive proxy statement Apr 29, 2013 230.7 KB  
DEF 14A definitive proxy statement Apr 29, 2013 346.8 KB  
PRE 14A preliminary proxy statement Apr 19, 2013 341.5 KB  
8-K current report Mar 21, 2013 62.3 KB  
10-K annual report Mar 12, 2013 1.2 MB  
8-K current report Mar 12, 2013 84.7 KB  
4 nisi, rudolph Jan 31, 2013 24.3 KB  
4 chin, richard Jan 31, 2013 24.3 KB  
4 galliker, stephen s Jan 31, 2013 24.3 KB  
4 ahn, mark j Jan 31, 2013 25.4 KB  
4 schwartz, mark w. Jan 31, 2013 25.6 KB  
4/A schwartz mark w. Jan 31, 2013 24.8 KB  
4 mazanet, rosemary Jan 31, 2013 24.5 KB  
4 kriegsman, steven a Jan 31, 2013 24.3 KB  
Showing 1-20 of 401 Page: 1 2 3 4 5 ... 21  Next 20
Email | Print
  • Home
  • Legal
  • Galena Biopharma. All rights reserved.

Contact:
info@GalenaBiopharma.com